Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fox Chase Cancer Center researchers make significant discovery about function of p53

03.02.2003


Cancer researchers have known that the tumor-suppressor gene p53 is critical in preventing cells from dividing inappropriately and becoming tumors. But now, researchers at Fox Chase Cancer Center have established that the ability of the p53 gene to perform its job depends on the type of p53 within each cell. This and another new finding about p53, published in Nature Genetics (Feb. 3, 2003 online version, March 2003 print version), have implications for tailoring chemotherapy, designing new cancer treatments, and understanding how to treat cancer in certain populations.



“The existence of two variants, or polymorphisms, of p53 isn’t new, but we’ve discovered that the variant type in each cell can influence its tumor-suppressor ability,” explains senior author Maureen Murphy, Ph.D., a molecular biologist in the pharmacology department of Fox Chase Cancer Center, Philadelphia, Pa.

When functioning properly, p53 polices cells for problems such as errant cellular growth, the hallmark of human cancer. If such harmful factors are present, p53 triggers the process of programmed cell death (known as apoptosis)-in effect, causing the “bad” cells to self-destruct. Alterations, or mutations, in this gene have been found in more than 60 percent of human cancers.


Murphy and her colleagues have known about the two p53 variants, but how the differences affect p53’s ability to suppress tumor development was not previously understood until now.

“People have one form or another of p53,” says Murphy. “The p53 variant containing the amino acid called arginine is better at killing out-of-control cells. The other p53 variant with the amino acid proline is less capable of stopping errant cells. When we asked if the two forms might function differently, the answer was a resounding yes.

“In terms of treating cancer, patients could potentially be typed for the kind of p53 they have, some day allowing physicians to tailor their therapy. If a patient has the arginine p53, which kills cells better, relatively less drugs might be needed for that person’s body to kill tumor cells. If another patient has the proline form, which is less active, relatively more drugs may be needed to fight the tumor.”

Although p53 variants have not received much attention from the biomedical community until now, epidemiologists have known that the proline form has an enhanced frequency in African Americans. This variant, which is less likely to set off programmed cell death, is more frequent in populations who live closer to the equator and have darker skin color. As a result, “p53 variants seem to differ according to ethnicity, and that might have implications for cancer treatment in different populations,” says Murphy.

The published research also redefines the function of p53. The p53 protein normally resides in the nucleus, and the way scientists have hypothesized its control of cell death is that it “turns on” the proteins that tell a cell to die or “turns off” the proteins that tell a cell to live. When the researchers couldn’t find a difference between the two forms with regard to activity inside the nucleus, they turned their attention to a little-studied area of p53 activity outside the nucleus—in the mitochondria, the energy storehouse of the cell.

“We looked at this and found a dramatic difference between the two forms,” recalls Murphy. They found that the arginine form, which is more efficient at killing cells, travels out of the nucleus better and into the mitochondria, where p53 functions to kill the cell.

Murphy adds, “Not only did we find a common polymorphism that influences tumor suppression, we also found that this seemingly obscure activity is at the center of how this protein kills cells.”

By bringing the mitochondrial pathway of cell death to the forefront of research, the investigators suggest that drugs could be designed to put p53 directly into the mitochondria or enable the cell to put it there. In the paper, they begin to test this hypothesis. They showed that if a drug is administered that prevents p53 from going to the mitochondria, then it inhibits the ability of p53 to kill a cell. Future efforts will focus on identifying drugs that enhance the ability of p53 to go to the mitochondria.


Fox Chase Cancer Center, one of the nation’s first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center’s web site at www.fccc.edu or call 1-888-FOX CHASE.

"The codon 72polymorphic variants of p53 demonstrate significant differences in apoptotic potential" Nature Genetics (Feb. 3, 2003 online version, March 2003 print version). http://press.nature.com.

This research was conducted equally by Patrick Dumont, a postdoctoral fellow in the Murphy lab, and Julie Leu, a postdoc in the lab of Donna L. George, from the Department of Genetics at the University of Pennsylvania School of Medicine. Anthony C. Della Pietra III from the Murphy lab also participated in the research.


Karen Mallet | EurekAlert!
Further information:
http://www.fccc.edu/
http://press.nature.com

More articles from Health and Medicine:

nachricht Diabetes mellitus: A risk factor for early colorectal cancer
27.05.2020 | Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

nachricht Ultra-thin fibres designed to protect nerves after brain surgery
27.05.2020 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Biotechnology: Triggered by light, a novel way to switch on an enzyme

In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".

Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...

Im Focus: New double-contrast technique picks up small tumors on MRI

Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.

researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...

Im Focus: I-call - When microimplants communicate with each other / Innovation driver digitization - "Smart Health“

Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.

When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...

Im Focus: When predictions of theoretical chemists become reality

Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.

Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...

Im Focus: Rolling into the deep

Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

Black nitrogen: Bayreuth researchers discover new high-pressure material and solve a puzzle of the periodic table

29.05.2020 | Materials Sciences

Argonne researchers create active material out of microscopic spinning particles

29.05.2020 | Materials Sciences

Smart windows that self-illuminate on rainy days

29.05.2020 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>